Filing Flows › AstraZeneca (AZN) › Takeover & LBO
Is AstraZeneca (AZN) a takeover target?
A leveraged buyout does not work for AstraZeneca on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-11-06): AstraZeneca stock weighs reported Rhythm takeover proposal.
Why a leveraged buyout does not fit
The buyout model needs AstraZeneca's revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-11-06 · news · AstraZeneca stock weighs reported Rhythm takeover proposal
AstraZeneca's latest quarter
AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart follows the revenue to costs, profit and cash.
Questions
Is AstraZeneca being acquired?
The latest signal on file is from 2026-11-06: AstraZeneca stock weighs reported Rhythm takeover proposal. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy AstraZeneca?
A leveraged buyout does not work for AstraZeneca on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.